Published in Biochim Biophys Acta on October 21, 1968
Clostridium botulinum neurotoxin. Microbiol Rev (1980) 2.89
Purification and characterization of two components of botulinum C2 toxin. Infect Immun (1980) 2.74
Purification and some properties of progenitor toxins of Clostridium botulinum type B. Infect Immun (1974) 2.48
Molecular construction of Clostridium botulinum type A toxins. Infect Immun (1975) 2.22
Purification of Clostridium botuliunum type F progenitor toxin. Appl Microbiol (1974) 2.16
Isolation and molecular size of Clostridium botulinum type C toxin. Appl Environ Microbiol (1977) 1.94
Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect Immun (1977) 1.92
Significance of 12S toxin of Clostridium botulinum type E. J Bacteriol (1969) 1.87
Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect Immun (1980) 1.67
Botulinal toxins and the problem of nomenclature of simple toxins. Bacteriol Rev (1971) 1.51
Activation of Clostridium botulinum type B toxin by an endogenous enzyme. J Bacteriol (1971) 1.49
Response of mouse intestinal loop to botulinum C2 toxin: enterotoxic activity induced by cooperation of nonlinked protein components. Infect Immun (1983) 1.41
Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect Immun (1977) 1.41
Vascular permeability activity of botulinum C2 toxin elicited by cooperation of two dissimilar protein components. Infect Immun (1981) 1.38
The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect Immun (1986) 1.30
Activation of botulinum toxins in the absence of nicking. Infect Immun (1977) 1.26
Antigenicites of fragments of Clostridium botulinum type B derivative toxin. Infect Immun (1975) 1.23
Simplified purification method for Clostridium botulinum type E toxin. Appl Environ Microbiol (1987) 1.14
Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type E toxin. Appl Environ Microbiol (1979) 1.09
Immunological characterization of Clostridium butyricum neurotoxin and its trypsin-induced fragment by use of monoclonal antibodies against Clostridium botulinum type E neurotoxin. Infect Immun (1991) 1.06
Acid precipitation of Clostridium botulinum type C and D toxins from whole culture by addition of ribonucleic acid as a precipitation aid. Infect Immun (1978) 1.03
Rapid detection of Clostridium botulinum toxin by capillary tube diffusion. Appl Microbiol (1974) 1.02
Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect Immun (1984) 1.00
Observations on toxin and hemagglutinin produced by Clostridium botulinum type C. Appl Environ Microbiol (1978) 0.94
Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin. Infect Immun (1977) 0.88
Universal and specific quantitative detection of botulinum neurotoxin genes. BMC Microbiol (2010) 0.82
PEG precipitation coupled with chromatography is a new and sufficient method for the purification of botulinum neurotoxin type B [corrected]. PLoS One (2012) 0.81
Clostridium botulinum type E toxin: effect of pH and method of purification on molecular weight. Appl Microbiol (1974) 0.75
Detection of type E botulinal toxin in cultures by fluorescent-antibody microscopy. Appl Microbiol (1973) 0.75
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol (1998) 11.26
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol (1999) 8.98
Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med (1996) 8.54
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 6.72
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Clinical features and management of hepatic portal venous gas: four case reports and cumulative review of the literature. Arch Surg (2001) 3.66
Mini-laparoscopic appendectomy using a needle loop retractor offers optimal cosmetic results. Surg Endosc (2004) 3.38
Purification and characterization of two components of botulinum C2 toxin. Infect Immun (1980) 2.74
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med (1994) 2.71
Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med (1982) 2.52
Effect of chronic administration of propranolol on lipoprotein composition. Metabolism (1976) 2.49
Purification and some properties of progenitor toxins of Clostridium botulinum type B. Infect Immun (1974) 2.48
Activity differentially regulates the surface expression of synaptic AMPA and NMDA glutamate receptors. Proc Natl Acad Sci U S A (1998) 2.28
Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol (2000) 2.24
Molecular construction of Clostridium botulinum type A toxins. Infect Immun (1975) 2.22
Purification of Clostridium botuliunum type F progenitor toxin. Appl Microbiol (1974) 2.16
Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J Exp Med (1982) 2.11
Clostridium botulinum toxins. Pharmacol Ther (1982) 2.03
Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. Mol Cell Biol (1998) 1.98
Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect Immun (1977) 1.92
Rapid bioassay for Clostridium botulinum type-E toxins by intravenous injection into mice. Jpn J Med Sci Biol (1968) 1.88
Germ-line transmission and developmental regulation of a 150-kb yeast artificial chromosome containing the human beta-globin locus in transgenic mice. Proc Natl Acad Sci U S A (1993) 1.88
Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg (1998) 1.88
Significance of 12S toxin of Clostridium botulinum type E. J Bacteriol (1969) 1.87
Purification and some properties of Aeromonas hydrophila hemolysin. Infect Immun (1984) 1.84
A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest (1999) 1.83
Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol (2001) 1.80
Evidence that botulinum C2 toxin has two dissimilar components. Infect Immun (1980) 1.77
Pathway of chymotrypsin evolution suggested by the structure of the FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F) Nat Struct Biol (1997) 1.75
Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun (1977) 1.75
Simplified method for purification of Clostridium perfringens type A enterotoxin. Appl Microbiol (1973) 1.71
Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect Immun (1980) 1.67
Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation (2000) 1.65
Remitting seronegative symmetrical synovitis with pitting edema associated with gastric carcinoma. J Rheumatol (1997) 1.64
Discrimination of brain abscess from necrotic or cystic tumors by diffusion-weighted echo planar imaging. Magn Reson Imaging (1996) 1.59
mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ (2011) 1.52
Botulinal toxins and the problem of nomenclature of simple toxins. Bacteriol Rev (1971) 1.51
Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J (1998) 1.50
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res (2000) 1.50
Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect Immun (1977) 1.48
Molecular construction of Clostridium botulinum type F progenitor toxin. Appl Microbiol (1975) 1.48
Physical and functional interactions of Doc2 and Munc13 in Ca2+-dependent exocytotic machinery. J Biol Chem (1997) 1.46
Familial occurrence of electrocardiographic abnormalities of the Brugada-type. Intern Med (1996) 1.45
Cross reaction in reversed passive hemagglutination between Clostridium botulinum type A and B toxins and its avoidance by the sue of anti-toxic component immunoglobulin isolated by affinity chromatography. Jpn J Med Sci Biol (1974) 1.43
Nationwide surveillance of antimicrobial consumption and resistance to Pseudomonas aeruginosa isolates at 203 Japanese hospitals in 2010. Infection (2013) 1.42
Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol (1996) 1.42
Sporulation and C2 toxin production by Clostridium botulinum type C strains producing no C1 toxin. Microbiol Immunol (1978) 1.41
Hydrogen peroxide induces midzonal heat shock protein 72 and apoptosis in sinusoidal endothelial cells of hypoxic rat liver. Crit Care Med (2000) 1.41
Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect Immun (1977) 1.41
Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol (1993) 1.40
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res (1996) 1.39
A small polypoid lesion in the lower common bile duct: a case study. Endoscopy (1994) 1.39
The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood (1997) 1.39
Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol (2001) 1.39
ADP-ribosylation of the rho/rac proteins induces growth inhibition, neurite outgrowth and acetylcholine esterase in cultured PC-12 cells. Biochem Biophys Res Commun (1990) 1.38
Vascular permeability activity of botulinum C2 toxin elicited by cooperation of two dissimilar protein components. Infect Immun (1981) 1.38
cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun (2001) 1.37
In vitro production of Clostridium perfringens enterotoxin and its detection by reversed passive hemagglutination. Appl Microbiol (1973) 1.36
The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect Immun (1986) 1.30
Specific changes in human brain after hypoglycemic injury. Stroke (1997) 1.30
Experimental botulism in chickens: the cecum as the site of production and absorption of botulinum toxin. Jpn J Med Sci Biol (1978) 1.29
Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D. Nucleic Acids Res (1990) 1.26
Activation of botulinum toxins in the absence of nicking. Infect Immun (1977) 1.26
Dissociation of Clostridium botulinum type-E-toxin. Biochem Biophys Res Commun (1967) 1.23
Rapid gas chromatographic analysis of microbial volatile metabolites. Jpn J Microbiol (1969) 1.23
Dissociation and reconstitution of 12-S toxin of Clostridium botulinum type E. Biochim Biophys Acta (1969) 1.23
Antigenicites of fragments of Clostridium botulinum type B derivative toxin. Infect Immun (1975) 1.23
Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet (1999) 1.22
Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol (2005) 1.22
Endothelial myosin light chain kinase regulates neutrophil migration across human umbilical vein endothelial cell monolayer. J Immunol (1998) 1.22
Aggressive surgery for carcinoma of the gallbladder. Surgery (1989) 1.20
Chromosomal variants among 1790 infertile men. Int J Urol (2001) 1.20
Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. J Periodontal Res (2003) 1.20
Delayed ischemic hyperintensity on T1-weighted MRI in the caudoputamen and cerebral cortex of humans after spectacular shrinking deficit. Stroke (1999) 1.19
Isolation and function of a Clostridium perfringens enterotoxin fragment. Infect Immun (1987) 1.19
Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta (1980) 1.18
Alterations of lipid metabolism in mice injected with endotoxin. Microbiol Immunol (1979) 1.18
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol (2000) 1.17
Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gan (1979) 1.16
Fluid accumulation in mouse ligated intestine inoculated with Clostridium perfringens enterotoxin. Appl Environ Microbiol (1979) 1.16
Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect Immun (1989) 1.15
Two cases of metastatic bladder cancers showing diffuse thickening of the bladder wall. Jpn J Clin Oncol (1999) 1.15
Oral toxicities of Clostridium botulinum type E toxins of different forms. Jpn J Med Sci Biol (1974) 1.14
Assay methods for Clostridium perfringens type A enterotoxin. Appl Microbiol (1973) 1.14
TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett (1986) 1.13
The beneficial effect of a prostaglandin I2 analog on ischemic rat liver. Transplantation (1991) 1.13
Surgery of the portal vein in resection of cancer of the hepatic hilus. Surgery (1986) 1.13
Immunologic and clinical studies on murine experimental autoimmune gastritis induced by neonatal thymectomy. Gastroenterology (1988) 1.12